PharmaCyte Biotech (NASDAQ:PMCB) Announces Earnings Results

PharmaCyte Biotech (NASDAQ:PMCB) released its earnings results on Friday. The company reported ($0.29) earnings per share for the quarter, Zacks reports.

PharmaCyte Biotech Price Performance

Shares of NASDAQ PMCB traded up $0.05 during mid-day trading on Friday, reaching $1.72. 8,228 shares of the company’s stock traded hands, compared to its average volume of 23,956. The business has a 50-day simple moving average of $1.75 and a 200 day simple moving average of $1.86. The stock has a market cap of $13.21 million, a P/E ratio of 2.62 and a beta of -0.21. PharmaCyte Biotech has a 1-year low of $1.39 and a 1-year high of $2.58.

PharmaCyte Biotech Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.